BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sparrow Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sparrow Pharmaceuticals's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07296484-512@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:clofutriben: Phase 2 readout est. (NCT07296484)
DESCRIPTION:clofutriben\, phase 2\, Type 2 Diabetes.\nStudy: Trial Against 
 INtractable Type 2 Diabetes (CAPTAIN-T2D)\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/clof
 utriben#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07296484
URL:https://assetmemo.bio/drug/clofutriben#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
